160 related articles for article (PubMed ID: 19917859)
1. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
Sohani AR; Ferry JA; Chang PS; Abramson JS
J Clin Oncol; 2010 Feb; 28(5):e69-72. PubMed ID: 19917859
[No Abstract] [Full Text] [Related]
2. EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient.
Janssens A; Berth M; De Paepe P; Verhasselt B; Van Roy N; Noens L; Philippé J; Offner F
Am J Hematol; 2006 Sep; 81(9):706-12. PubMed ID: 16838338
[TBL] [Abstract][Full Text] [Related]
3. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
Roch N; Salameire D; Gressin R; Morand P; Epaulard O; Pavese P; Brion JP; Stahl JP
Scand J Infect Dis; 2008; 40(4):343-6. PubMed ID: 17934981
[TBL] [Abstract][Full Text] [Related]
4. EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab.
van de Langerijt B; Doorduijn JK; Lam KH; van den Bent MJ
J Neurol; 2011 May; 258(5):944-5. PubMed ID: 21136270
[No Abstract] [Full Text] [Related]
5. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
Madaris L
J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
[TBL] [Abstract][Full Text] [Related]
6. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab.
Ghobrial IM; Otteman LA; White WL
N Engl J Med; 2003 Dec; 349(26):2570-2; discussion 2570-2. PubMed ID: 14695424
[No Abstract] [Full Text] [Related]
7. Synchronous Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly and Epstein-Barr virus-positive classical Hodgkin lymphoma.
Hwang YY; Leung AY; Lau WH; Loong F; So JC; Tse E; Kwong YL
Histopathology; 2011 Aug; 59(2):352-5. PubMed ID: 21884219
[No Abstract] [Full Text] [Related]
8. Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
Weisel KC; Weidmann E; Anagnostopoulos I; Kanz L; Pezzutto A; Subklewe M
Int J Hematol; 2008 Nov; 88(4):434-440. PubMed ID: 18839273
[TBL] [Abstract][Full Text] [Related]
9. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
10. Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.
Meeuse JJ; Sprenger HG; van Assen S; Leduc D; Daenen SM; Arends JP; van der Werf TS
Emerg Infect Dis; 2007 Dec; 13(12):1942-3. PubMed ID: 18258054
[TBL] [Abstract][Full Text] [Related]
11. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
Abbi KK; Rizvi SM; Sivik J; Thyagarajan S; Loughran T; Drabick JJ
Leuk Res; 2010 Jul; 34(7):e154-6. PubMed ID: 20362332
[No Abstract] [Full Text] [Related]
12. Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab.
Ichikawa S; Fukuhara N; Saito K; Yokoyama H; Onodera K; Onishi Y; Ichinohasama R; Harigae H
Leuk Lymphoma; 2020 Jun; 61(6):1504-1507. PubMed ID: 31960738
[No Abstract] [Full Text] [Related]
13. EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia.
Suleman A; Tsui H; Ghorab Z; Lam PW; Mozessohn L
Ann Hematol; 2023 Feb; 102(2):471-472. PubMed ID: 36441259
[No Abstract] [Full Text] [Related]
14. Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia.
Yong HX; Linn YC; Ong KH; Tan D
Leuk Res; 2012 Aug; 36(8):e163-5. PubMed ID: 22613190
[No Abstract] [Full Text] [Related]
15. CD30-positive EBV-associated diffuse large B-cell lymphoma occurring after immunosuppressive therapy for T-cell prolymphocytic leukemia.
Alduaij A; Treaba DO; Winer ES
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):64-7. PubMed ID: 21454193
[TBL] [Abstract][Full Text] [Related]
16. Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma.
Sirvent-Von Bueltzingsloewen A; Sirvent N; Morand P; Cassuto JP
Med Pediatr Oncol; 2003 Jun; 40(6):408-9. PubMed ID: 12692818
[No Abstract] [Full Text] [Related]
17. Epstein-Barr virus associated large B-cell cardiac lymphoma with simultaneous manifestation in the forearm.
Qedra N; Assaf C; Dürkop H; Komoda T; Kadry M; Hetzer R
J Clin Oncol; 2008 Nov; 26(32):5301-3. PubMed ID: 18854558
[No Abstract] [Full Text] [Related]
18. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
Cooles FA; Jackson GH; Menon G; Isaacs JD
Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
[No Abstract] [Full Text] [Related]
19. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
20. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
Orlandi EM; Baldanti F; Citro A; Pochintesta L; Gatti M; Lazzarino M
Haematologica; 2008 Nov; 93(11):1758-60. PubMed ID: 18790800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
